Evidence map›Paper›PMID 39468199›Full record

ArticleScientific reports2024

A single-center analysis of clonal transmission of carbapenem-resistant Acinetobacter baumannii among intensive care unit patients during the COVID-19 pandemic.

Masoud Azimzadeh, Abbas Bahador, Somaye Shiralizadeh, Parisa Mahshouri, Ladan Akbari, Sama Makari, Atefeh Rezaei, Mohammad Sina Alikhani, Mohammad Yousef Alikhani

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Changes in Susceptibility Profiles ofJournal of clinical medicine · 2026
    Article
  2. Carbapenem-resistantFrontiers in medicine · 2026
    Article
  3. Article
  4. Evaluation of Infections Caused by Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025
    Article
  5. Bacteriological Spectrum and Drug Resistance Among Patients Associated With Bloodstream Infection in Intensive Care Units in the Affiliated Hospital of Jiaxing University From 2021 to 2023.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Masoud AzimzadehDepartment of Microbiology, Hamadan University of Medical Sciences, Hamadan, Iran.
Abbas BahadorDepartment of Microbiology, Tehran University of Medical Sciences, Tehran, Iran.
Somaye ShiralizadehDepartment of Microbiology, Hamadan University of Medical Sciences, Hamadan, Iran.
Parisa MahshouriDepartment of Microbiology, Hamadan University of Medical Sciences, Hamadan, Iran.
Ladan AkbariDepartment of Microbiology, Hamadan University of Medical Sciences, Hamadan, Iran.
Sama MakariDepartment of Microbiology, Hamadan University of Medical Sciences, Hamadan, Iran.
Atefeh RezaeiDepartment of Microbiology, Hamadan University of Medical Sciences, Hamadan, Iran.
Mohammad Sina AlikhaniStudent Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran.
Mohammad Yousef AlikhaniDepartment of Microbiology, Hamadan University of Medical Sciences, Hamadan, Iran. alikhani43@yahoo.com.ORCID https://orcid.org/0000-0003-4577-4029

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenem-Resistant Acinetobacter baumannii (CRAB) outbreak in intensive care units (ICUs) is a significant problem for healthcare facilities. In this study, we aimed to investigate the occurrence of CRAB isolates among ICU-admitted patients during the three waves of the COVID-19 pandemic in Iran using Multiple-Locus Variable Number Tandem-Repeat Analysis (MLVA). We obtained 50 (A) baumannii isolates from tracheal aspirate and blood culture samples. In the disc diffusion method, all isolates were cefotaxime, ceftriaxone, and cefepime-resistant, while 98% (49/50) of isolates were resistant to piperacillin, piperacillin-tazobactam, ceftazidime, and ciprofloxacin. Levofloxacin and tobramycin resistance was found in 76% (38/50) of isolates. In the microbroth dilution test all isolates were resistant to imipenem, 98% (49/50) to meropenem, 68% (34/50) to colistin, and 20% (10/50) to polymyxin (B) Based on the PCR findings, all isolates harbored bla

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsCarbapenemsCOVID-19Intensive Care UnitsAdultAgedbeta-LactamasesDrug Resistance, Multiple, BacterialFemaleHumansIranMaleMicrobial Sensitivity TestsMiddle AgedAnti-Bacterial Agentsbeta-LactamasesCarbapenemsCarbapenem-Resistant Acinetobacter baumanniiCOVID-19DendrogramESBLMBLMinimum spanning treeMLVA

Identifiers

PMID39468199
PMCPMC11519864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.